JUN 03, 2019 3:42 PM PDT

Making Cancer Language Patient-Friendly: A Multisector Call to Action

WRITTEN BY: Julia Travers

A May 2019 article in The Oncologist calls on members of the medical community to cooperatively create a resource of patient-friendly language for people navigating cancer treatment. The authors hail from various oncology-related offices of the U.S. Food and Drug Administration (FDA), and they recommend a multisector approach to help patients better understand essential oncology terminology in relation to treatment and trial decisions.

“We have increasingly learned from patient engagement and [FDA] public workshops that many patients have difficulty understanding trial terminology intended to convey a treatment’s benefit and the harms that may be associated with its use,” the authors write.

Patient with doctor illustration, credit: public domain

Progression-free survival, disease-free survival, overall survival and overall response rate are some of the concepts that may be under-explained or unclear to patients. The article proposes oncologists, members of the pharmaceutical industry, nurses, pharmacists, regulatory agencies, payers, health care providers and patient advocacy groups team up with patients to address this dilemma.

To tackle this problem, three general steps are suggested; the first is to work with patients and advocates to develop a better understanding of the issue and the content areas that are most in need of clarification. In the next stage, definitions of common terms could be “generated in an iterative dialogue” between patients and medical professionals.

The authors envision the development of an agreed-upon set of patient-friendly definitions, which could, in the third step of their suggested action plan, be communicated through multiple avenues, such as online resources, provider education campaigns and patient advocacy groups. For example, drawing on their interactions and conversations with patient groups so far, they came up with the following patient-friendly explanation of progression-free survival: “the median length of time after the start of this treatment that patients are alive while their cancer does not grow or spread.”

Patient with doctor, credit: public domain

The authors also point out that patient advocates are an increasingly vital resource for people with cancer, though many patients remain unaware of their existence. “This is especially true for medically underserved populations, including racial and ethnic minorities and individuals of lower socioeconomic status, as their ability to access health care is often more limited,” the authors state. Given this current imbalance, connecting more cancer patients to advocates will likely be an integral component of a successful patient-friendly language initiative.

About the Author
  • Julia Travers is a writer, artist and teacher. She frequently covers science, tech, conservation and the arts. She enjoys solutions journalism. Find more of her work at jtravers.journoportfolio.com.
You May Also Like
OCT 06, 2020
Drug Discovery & Development
New Immunotherapy Drug Effective Against Lung Cancer
OCT 06, 2020
New Immunotherapy Drug Effective Against Lung Cancer
A new study has confirmed that Tecentriq, an immunotherapy drug, improves survival rates among those with newly diagnose ...
OCT 05, 2020
Cancer
Fighting mitochondrial terminal exhaustion
OCT 05, 2020
Fighting mitochondrial terminal exhaustion
New findings reported in Nature Immunology highlight how the tumor microenvironment attacks the mitochondria of T l ...
OCT 18, 2020
Microbiology
Mouth Microbes Play a Role in Oral Cancer Development
OCT 18, 2020
Mouth Microbes Play a Role in Oral Cancer Development
Oral hygiene is not only important for keeping teeth and gums healthy; it can also affect a person's health in general.
NOV 02, 2020
Immunology
New Cancer Drug Reboots Stalled Immunotherapies
NOV 02, 2020
New Cancer Drug Reboots Stalled Immunotherapies
In contrast to traditional chemotherapies, immunotherapies reprogram the patient’s own immune system to fight tumo ...
NOV 15, 2020
Genetics & Genomics
Novel Cancer-Driving Genes are Discovered
NOV 15, 2020
Novel Cancer-Driving Genes are Discovered
Cells have to be able to divide so new ones can replenish cells that get worn out, dysfunctional, or that accumulate dam ...
NOV 14, 2020
Cancer
New intravenous anti-cancer therapy crosses blood-brain barrier
NOV 14, 2020
New intravenous anti-cancer therapy crosses blood-brain barrier
New research from the University of Michigan reports for the first time a new synthetic protein nanoparticle that is abl ...
Loading Comments...